II. Indications
- FDA Approved (in combination regimens)
- Off-Label Use
- Graft Versus Host Disease (acute or chronic)
- Chronic Lymphocytic Leukemia (CLL)
- Cutaneous T-Cell Lymphoma
- Mycosis Fungoides
- T-Cell Prolymphocytic Leukemia
III. Mechanism
- Purine Nucleotide analog
- Extracted from bacterium Streptomyces antibioticus
- More active in lymph cells, esp. T-Cells, and esp. malignant T Cells and CD26+ Lymphocytes
- Inhibits adenine deaminase (ADA)
- Blocks Purine metabolism
- Increases intracellular dATP levels, inhibiting ribonucleotide reductase
- Inhibits DNA synthesis
- Inhibits RNA synthesis
IV. Medications
- Pentostatin powder for IV Solution in 10 mg vials
V. Dosing
- See other references for disease specific dosing protocols
VI. Adverse Effects
VII. Safety
- Avoid in Pregnancy (any trimester)
- Use reliable Contraception
- Avoid in Lactation
- Monitoring
VIII. Resources
IX. References
- Hamilton (2020) Tarascon Pocket Pharmacopoeia